Piper Sandler Reiterates Overweight Rating on Sutro Biopharma (STRO)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St subdued as markets pause after S&P record high; data, Mideast in focus
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
TD Cowen Reiterates Buy Rating on Sutro Biopharma (STRO)
September 16, 2024 9:11 AM EDTTD Cowen analyst Tara Bancroft reiterated a Buy rating on Sutro Biopharma (NASDAQ: STRO).
The analyst commented, "Luvelta+bev's 35% ORR in an unselected population and multiple doses is impressive on its own given that Elahere+bev had a 44% ORR in higher... More
